Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2000Blood

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines

View Full Paper
Ask AI
Bookmark
Share

Authors

EWEllen WeisbergHarvard UniversityJGJames D. GriffinBrigham Young University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Weisberg et al. (2000) studied this question.

synapsesocial.com/papers/6a12fdb917455f99e89e6fb6https://doi.org/10.1182/blood.v95.11.3498
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.1992 · 322 citations
  2. 2Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCR1998 · 236 citations
  3. 3CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins1997 · 519 citations
  4. 4The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells1997 · 628 citations
  5. 5A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.1993 · 420 citations